Porcine Vaccine Market Size and Forecasts (2021 - 2031), Global and Regional Share, Trends, and Growth Opportunity Analysis

Coverage: Porcine Vaccine Market covers analysis By Technology (Inactivated Vaccines, Live Attenuated Vaccines, Toxoid Vaccines, Recombinant Vaccines, Conjugate Vaccines, DNA Vaccines); Disease Indication (Diarrhea, Swine Influenza, Arthritis, Bordatella Rhinitis, Porcine Reproductive and Respiratory Virus (PRRSV), Porcine Circovirus Associated Disease (PCVAD), Others); End User (Veterinary Hospitals, Hog/Pig Production Farm), and Geography (North America, Europe, Asia Pacific, and South and Central America)

  • Report Code : TIPRE00021695
  • Category : Life Sciences
  • Status : Upcoming
  • No. of Pages : 150
Buy Now

MARKET INTRODUCTION



Infection of swine with porcine parvovirus (PPV) is reported across the world, which may be resulted into reproductive failure in swine or cutaneous lesions in piglets. The first vaccine to aid in the prevention of the porcine reproductive and respiratory syndrome (PRRS) was approved for use in Spain in 1994, since then a number of additional vaccines (comprising either attenuated or inactivated PRRSV) have been developed in the U.S. and Europe. These vaccines include a different strain of the virus of either the North American or European genotype. According to an article published in NCBI, in 2021, around 70% of pig producers are small farmers with farms fewer than 50 pigs each, and hygienic measures and feed of the pigs is not controlled, which has raised demand for porcine vaccines market.

MARKET DYNAMICS



Porcine vaccine market is driving due to factors such as increasing incidences of zoonotic diseases, increasing number of biotechnology companies, research institutes engaged in research and development of porcine vaccines, and government initiatives for funding agriculture and animal husbandry sector. However, the high cost of maintaining, handling, and storage of vaccines is likely to create a negative impact on the growth of this market.

MARKET SCOPE



The Porcine vaccine market analysis to 2031 is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of Porcine vaccine Market with detailed market segmentation by technology, disease indication and end user. The Porcine vaccine Market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in Porcine vaccine market and offers key trends and opportunities in the market.

MARKET SEGMENTATION



The Porcine vaccine market is segmented based on technology, disease indication and end user. Based on technology, market is segmented as inactivated vaccines, live attenuated vaccines, toxoid vaccines, recombinant vaccines, conjugate vaccines, DNA vaccines. Based on disease indication, market is segmented as diarrhea, swine influenza, arthritis, Bordetella rhinitis, porcine reproductive and respiratory virus (PRRSV), porcine circovirus associated disease (PCVAD), others. Based on end user, market is segmented as veterinary hospitals, hog/pig production farm.

REGIONAL FRAMEWORK



The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the Porcine vaccine market based on various segments. It also provides market size and forecast estimates from year 2021 to 2031 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The Porcine vaccine market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting Porcine vaccine market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Porcine vaccine market in these regions.

MARKET PLAYERS



The report covers key developments in the Porcine vaccine market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as Application and End user launches, Application and End user approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from Porcine vaccine market are anticipated to have lucrative growth opportunities in the future with the rising demand for Porcine vaccine in the global market. Below mentioned is the list of few companies engaged in the Porcine vaccine Market.

The report also includes the profiles of key players in Porcine vaccine market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.

  •   Bayer AG
  •   Bimeda Animal Health
  •   Boehringer Ingelheim GmbH
  •   Ceva Sante Animale
  •   Eli Lilly and Company
  •   Merck and Co., Inc.
  •   Sanofi S.A
  •   Vetoquinol
  •   Zoetis, Inc.
  •   Hipra
  •   Elanco
  •   Formosa Biomedical Inc.
  •   Shoken Pharmaceutical Co., Ltd
  •   MSD Animal Health

The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.

Porcine Vaccine Report Scope

Report Attribute Details
Market size in 2023 US$ XX Million
Market Size by 2031 US$ XX Million
Global CAGR (2023 - 2031) XX%
Historical Data 2021-2022
Forecast period 2024-2031
Segments Covered By Technology
  • Inactivated Vaccines
  • Live Attenuated Vaccines
  • Toxoid Vaccines
  • Recombinant Vaccines
  • Conjugate Vaccines
  • DNA Vaccines
By Disease Indication
  • Diarrhea
  • Swine Influenza
  • Arthritis
  • Bordatella Rhinitis
  • Porcine Reproductive and Respiratory Virus
  • Porcine Circovirus Associated Disease
By End User
  • Veterinary Hospitals
  • Hog/Pig Production Farm
Regions and Countries Covered North America
  • US
  • Canada
  • Mexico
Europe
  • UK
  • Germany
  • France
  • Russia
  • Italy
  • Rest of Europe
Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
South and Central America
  • Brazil
  • Argentina
  • Rest of South and Central America
Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa
Market leaders and key company profiles
  • Bayer AG
  • Bimeda Animal Health
  • Boehringer Ingelheim GmbH
  • Ceva Sante Animale
  • Eli Lilly and Company
  • Merck and Co., Inc.
  • Sanofi S.A
  • Vetoquinol
  • Zoetis, Inc.
    • Historical Analysis (2 Years), Base Year, Forecast (7 Years) with CAGR
    • PEST and SWOT Analysis
    • Market Size Value / Volume - Global, Regional, Country
    • Industry and Competitive Landscape
    • Excel Dataset
    Report Coverage

    Report Coverage

    Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

    Segment Covered

    Segment Covered

    This text is related
    to segments covered.

    Regional Scope

    Regional Scope

    North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

    Country Scope

    Country Scope

    This text is related
    to country scope.

    Trends and growth analysis reports related to Life Sciences : READ MORE..   

    The List of Companies

    1. Bayer AG
    2. Bimeda Animal Health
    3. Boehringer Ingelheim GmbH
    4. Ceva Sante Animale
    5. Eli Lilly and Company
    6. Merck and Co., Inc.
    7. Sanofi S.A
    8. Vetoquinol
    9. Zoetis, Inc.
    10. Hipra
    11. Elanco
    12. Formosa Biomedical Inc.
    13. Shoken Pharmaceutical Co., Ltd
    14. MSD Animal Health

    Buy Now